Establishing a reliable framework for harnessing the creative power of the scientific crowd
暂无分享,去创建一个
[1] G. Rao,et al. Open Innovation , 2019, Strategic Decisions.
[2] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[3] Kim Bure,et al. Open Access Could Transform Drug Discovery: A Case Study of JQ1 , 2016, Expert opinion on drug discovery.
[4] Mulin Jun Li,et al. Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .
[5] M. Daly,et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.
[6] Wen Hwa Lee,et al. Open Access Target Validation Is a More Efficient Way to Accelerate Drug Discovery , 2015, PLoS biology.
[7] Asher Mullard,et al. 2010 FDA drug approvals , 2011, Nature Reviews Drug Discovery.
[8] N. Savage. Competition: Unlikely partnerships , 2016, Nature.
[9] C. Vakoc,et al. A rationale to target the SWI/SNF complex for cancer therapy. , 2014, Trends in genetics : TIG.
[10] R. W. Hansen,et al. Journal of Health Economics , 2016 .
[11] G. Hirsch,et al. Curing Consortium Fatigue , 2013, Science Translational Medicine.
[12] B. Huggett. Reinventing tech transfer , 2014, Nature Biotechnology.
[13] S. Knapp,et al. Probing the epigenome. , 2015, Nature chemical biology.
[14] Ammon Salter,et al. Cui Bono? The Selective Revealing of Knowledge and Its Implications for Innovative Activity , 2012 .
[15] E. Schönbrunn,et al. An Advanced Tool To Interrogate BRD9. , 2016, Journal of medicinal chemistry.
[16] A. Edwards,et al. Reproducibility: Team up with industry , 2016, Nature.
[17] M. Kinch. 2014 in review: FDA approval of new drugs. , 2017, Drug discovery today.
[18] John P. Overington,et al. The promise and peril of chemical probes. , 2015, Nature chemical biology.
[19] Joel Cutcher-Gershenfeld,et al. Precompetitive consortia in biomedicine—how are we doing? , 2013, Nature Biotechnology.
[20] A new chapter in innovation , 2016, Nature.
[21] J. Henkel. Selective revealing in open innovation processes: the case of embedded Linux (gekürzte Version) , 2006 .
[22] Eric Bender,et al. Challenges: Crowdsourced solutions , 2016, Nature.
[23] Ragu Bharadwaj,et al. Crowdsourcing in pharma: a strategic framework. , 2015, Drug discovery today.
[24] S. Knapp,et al. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor , 2016, Journal of medicinal chemistry.
[25] Arthur S Slutsky,et al. Preclinical target validation using patient-derived cells , 2015, Nature Reviews Drug Discovery.
[26] Peter H. Salus,et al. The Daemon, the Gnu, and the Penguin , 2008 .
[27] Monika Lessl,et al. Grants4Targets: an open innovation initiative to foster drug discovery collaborations , 2014, Nature Reviews Drug Discovery.
[28] T. Willson,et al. Open access chemical and clinical probes to support drug discovery. , 2009, Nature chemical biology.
[29] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[30] Toshihiro Tanaka. The International HapMap Project , 2003, Nature.